Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
9.850
-0.320 (-3.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
August 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 22, 2023
Via
Benzinga
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
August 18, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
August 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
July 25, 2023
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
July 17, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
July 10, 2023
Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
July 07, 2023
Via
Benzinga
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
June 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
June 22, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
June 20, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
June 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
June 14, 2023
Participating institutional investors include Bridgewest Group
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
June 12, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
May 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 26, 2023
Via
Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
May 22, 2023
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
Via
Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
↗
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 22, 2023
Via
Benzinga
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
↗
May 22, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
May 22, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Via
InvestorPlace
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
May 04, 2023
•Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
What's Going On With Immix Biopharma Stock Today
↗
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 03, 2023
Via
Benzinga
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
May 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
April 27, 2023
Via
Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
April 27, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its...
Via
Benzinga
Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
↗
April 27, 2023
Gainers
Via
Benzinga
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
April 04, 2023
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
